Glycostem presents virtually at Innate Killer Summit 2020 our production system for off-the-Shelf, GMP Compliant, fully closed & semi-automated large-scale (oNKord^®) from fresh umbilical cord blood stem cells.

Glycostem is honored being seleced to be part of SVB Leerink Biopharma Private Company Connect on 7^th to 9^th July. It is a series of 1:1 between investors and Glycostem, one of the last formally organized investor conferences before the European summer break.

Glycostem CEO Troels Jordansen presents on 25^th June at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. 

Glycostem is  invited to the second largest investor conference: the Jefferies Virtual Healthcare Conference on 4^th July. The interest in off-the-shelf NK-cells with no CRS issues is increasing rapidly.

Glycostem presents at ACCESS CHINA Online Partnering Day on 15^th May, 2020. ACCESS CHINA Partnering Day is the largest online corporate access event between China and Western Biopharma Industry. Glycostem is looking for investors and partnering opportunities.

On 14^th May Glycostem presents virtually a poster at ASGCT 2020 about oNKord^® “off-the-shelf” NK therapy closed system manufacturing process and clinical potential in AML, with a perspective on CAR-NK and other NK innovative therapies.